Emerging therapeutic targets for osteoporosis treatment

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 7, 2014, Pages 817-831

  Chen, Minglei ^a   Qiao, Hongzhi ^a   Su, Zhigui ^a   Li, Huipeng ^a   Ping, Qineng ^a   Zong, Li ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anabolic agents; Antiresorptive agents; Bone remodeling; Osteoporosis; Signaling pathway

Indexed keywords

ALPHA5BETA3 INTEGRIN ANTAGONIST; ANABOLIC AGENT; BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CAT K INHIBITOR; CLC 7 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SEMAPHORIN; SEX HORMONE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; WNT PROTEIN; BONE DENSITY CONSERVATION AGENT;

BONE CELL; BONE REMODELING; CELL FUSION; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ESTROGEN THERAPY; HUMAN; MOLECULE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PUBLIC HEALTH; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PHYSIOLOGY;

ANABOLIC AGENTS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; HUMANS; OSTEOCLASTS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 84902435976     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.912632     Document Type: Review

References (134)

1. Luhmann T, Germershaus O, Groll J, et al. Bone targeting for the treatment of osteoporosis. J Control Release 2012;161:198-213
2. Kanakamani J, Tandon N. Newer therapies in osteoporosis. Indian J Rheumatol 2008;3:148-57
3. Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr 2009;19:219-33
4. Lim V, Clarke BL. New therapeutic targets for osteoporosis: beyond denosumab. Maturitas 2012;73:269-72
5. Sipos W, Pietschmann P, Rauner M, et al. Pathophysiology of osteoporosis. Wien Med Wochenschr 2009;159:230-4
6. Ralston SH. Structure and metabolism of bone. Medicine 2005;33:58-60
7. Allen JG, Fotsch C, Babij P. Emerging targets in osteoporosis disease modification. J Med Chem 2010;53:4332-53
8. Gallagher JC, Sai AJ. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas 2010;65:301-7
9. Lehenkari P, Hentunen TA, Laitala-Leinonen T, et al. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp Cell Res 1998;242:128-37
10. McMahon C, Will A, Hu P, et al. Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome. Blood 2001;97:1947-50
11. Yagi M, Ninomiya K, Fujita N, et al. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res 2007;22:992-1001
12. Miyamoto H, Suzuki T, Miyauchi Y, et al. Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res 2012;27:1289-97
13. Lee SH, Rho J, Jeong D, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 2006;12:1403-9
14. Iwasaki R, Ninomiya K, Miyamoto K, et al. Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity. Biochem Biophys Res Commun 2008;377:899-904
15. Bai YD, Yang FS, Xuan K, et al. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment. Med Hypotheses 2008;71:256-8
16. Kapur RP, Yao Z, Iida MH, et al. Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. J Bone Miner Res 2004;19:1689-97
17. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-46
18. Kim HH, Lee DE, Shin JN, et al. Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 1999;443:297-302
19. Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4:353-62
20. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-24
21. Zawawi MS, Dharmapatni AA, Cantley MD, et al. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation. Biochem Biophys Res Commun 2012;427:404-9
22. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901
23. Hirotani H, Tuohy NA, Woo JT, et al. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 2004;279:13984-92
24. Kim K, Kim JH, Lee J, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 2005;280:35209-16
25. Koga T, Inui M, Inoue K, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428:758-63
26. Mocsai A, Humphrey MB, Van Ziffle JA, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004;101:6158-63
27. Koga T, Matsui Y, Asagiri M, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005;11:880-5
28. Miyauchi Y, Ninomiya K, Miyamoto H, et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 2010;207:751-62
29. Miyauchi Y, Miyamoto H, Yoshida S, et al. Conditional inactivation of Blimp1 in adult mice promotes increased bone mass. J Biol Chem 2012;287:28508-17
30. Nishikawa K, Nakashima T, Hayashi M, et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci USA 2010;107:3117-22
31. Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/ RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457-75
32. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/ S6 kinase. Cell Death Differ 2003;10:1165-77
33. Kostenuik PJ, Bolon B, Morony S, et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-64
34. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57
35. Cho SW, Sun HJ, Yang JY, et al. Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther 2009;17:1979-87
36. Teitelbaum SL. Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 2000;18:344-9
37. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000;105:433-40
38. Horne WC, Neff L, Chatterjee D, et al. Osteoclasts express high levels of pp60csrc in association with intracellular membranes. J Cell Biol 1992;119:1003-13
39. Sanjay A, Houghton A, Neff L, et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta (3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001;152:181-95
40. Tanaka S, Amling M, Neff L, et al. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 1996;383:528-31
41. Nakamura I, Jimi E, Duong LT, et al. Tyrosine phosphorylation of p130Cas is involved in actin organization in osteoclasts. J Biol Chem 1998;273:11144-9
42. Nakamura I, Duong LT, Rodan SB, et al. Involvement of alphavbeta3 integrins in osteoclast function. J Bone Miner Metab 2007;25:337-44
43. Carron CP, Meyer DM, Engleman VW, et al. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 2000;165:587-98
44. Murphy MG, Cerchio K, Stoch SA, et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005;90:2022-8
45. Zhao Q, Wei Q, He A, et al. CLC-7: a potential therapeutic target for the treatment of osteoporosis and neurodegeneration. Biochem Biophys Res Commun 2009;384:277-9
46. Kornak U, Kasper D, Bosl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001;104:205-15
47. Kasper D, Planells-Cases R, Fuhrmann JC, et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005;24:1079-91
48. Chalhoub N, Benachenhou N, Rajapurohitam V, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 2003;9:399-406
49. Lange PF, Wartosch L, Jentsch TJ, et al. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 2006;440:220-3
50. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor N53736 prevents bone resorption in ovariectomized rats without changing bone formation. Wiley, Hoboken, NJ, ETATS-UNIS; 2004. p. 10
51. Schaller S, Henriksen K, Sorensen MG, et al. The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. Drug News Perspect 2005;18:489-95
52. Troen BR. The role of cathepsin K in normal bone resorption. Drug News Perspect 2004;17:19-28
53. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009;44:199-207
54. Li CY, Jepsen KJ, Majeska RJ, et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 2006;21:865-75
55. Balkan W, Martinez AF, Fernandez I, et al. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene 2009;446:90-8
56. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81
57. Duong le T. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep 2012;1:67
58. Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrixderived growth factor degradation by human osteoclasts. Bone 2008;42:200-11
59. Pennypacker BL, Duong le T, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2011;26:252-62
60. Venken K, Callewaert F, Boonen S, et al. Sex hormones, their receptors and bone health. Osteoporos Int 2008;19:1517-25
61. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203-4
62. Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996;2:1132-6
63. Michael H, Harkonen PL, Vaananen HK, et al. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005;20:2224-32
64. Chen J, Kim J, Dalton JT. Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv 2005;5:173-88
65. Taylor HS. Designing the ideal selective estrogen receptor modulator - an achievable goal? Menopause 2009;16:609-15
66. Wang Y, Panasiuk A, Grainger DW. Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Mol Pharm 2011;8:1016-24
67. Lin W-P, Lin J. Parathyroid hormone for osteoporosis treatment. Formos J Musculoskelet Disord 2011;2:113-17
68. Silva BC, Costa AG, Cusano NE, et al. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest 2011;34:801-10
69. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal 2009;21:1245-54
70. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40:1434-46
71. Qin L, Li X, Ko JK, et al. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 2005;280:3104-11
72. Datta NS, Chen C, Berry JE, et al. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res 2005;20:1051-64
73. Yamaguchi M, Ogata N, Shinoda Y, et al. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 2005;146:2620-8
74. Hurley MM, Okada Y, Xiao L, et al. Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2 +/- mice. Biochem Biophys Res Commun 2006;341:989-94
75. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005;37:148-58
76. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000;21:393-411
77. Tang CH, Yang RS, Chien MY, et al. Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts. Eur J Pharmacol 2008;579:40-9
78. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005;16:251-63
79. Jia TL, Wang HZ, Xie LP, et al. Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem Pharmacol 2003;65:709-15
80. Sugama R, Koike T, Imai Y, et al. Bone morphogenetic protein activities are enhanced by 3,5-cyclic adenosine monophosphate through suppression of Smad6 expression in osteoprogenitor cells. Bone 2006;38:206-14
81. Marie PJ. Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 2008;473:98-105
82. Lee MH, Kim YJ, Kim HJ, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003;278:34387-94
83. Tou L, Quibria N, Alexander JM. Transcriptional regulation of the human Runx2/Cbfa1 gene promoter by bone morphogenetic protein-7. Mol Cell Endocrinol 2003;205:121-9
84. Guicheux J, Lemonnier J, Ghayor C, et al. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-8
85. Wirries A, Schubert AK, Zimmermann R, et al. Thymoquinone accelerates osteoblast differentiation and activates bone morphogenetic protein-2 and ERK pathway. Int Immunopharmacol 2013;15:381-6
86. Niu T, Rosen CJ. The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene 2005;361:38-56
87. Paccou J, Dewailly J, Cortet B. Reduced levels of serum IGF-1 is related to the presence of osteoporotic fractures in male idiopathic osteoporosis. Joint Bone Spine 2012;79:78-82
88. Rozakis-Adcock M, McGlade J, Mbamalu G, et al. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992;360:689-92
89. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65
90. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001;2:760-8
91. Fujita T, Azuma Y, Fukuyama R, et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3KAkt signaling. J Cell Biol 2004;166:85-95
92. Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 1997;138:3849-58
93. Neuberg M, Buckbinder L, Seizinger B, et al. The p53/IGF-1 receptor axis in the regulation of programmed cell death. Endocrine 1997;7:107-9
94. Dupont J, Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today 2003;69:257-71
95. Janssens K, ten Dijke P, Janssens S, et al. Transforming growth factor-beta1 to the bone. Endocr Rev 2005;26:743-74
96. Alliston T, Choy L, Ducy P, et al. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001;20:2254-72
97. Yasui T, Kadono Y, Nakamura M, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res 2011;26:1447-56
98. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810
99. Luo W, Zou H, Jin L, et al. Axin contains three separable domains that confer intramolecular, homodimeric, and heterodimeric interactions involved in distinct functions. J Biol Chem 2005;280:5054-60
100. MacDonald BT, Tamai K, He X. Wnt/ beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26
101. Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934-45
102. Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006;39:754-66
103. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-9
104. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-88
105. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-59
106. Etheridge SL, Spencer GJ, Heath DJ, et al. Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 2004;22:849-60
107. Hu H, Hilton MJ, Tu X, et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005;132:49-60
108. Boland GM, Perkins G, Hall DJ, et al. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004;93:1210-30
109. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324-9
110. Longo KA, Wright WS, Kang S, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 2004;279:35503-9
111. Kulkarni NH, Onyia JE, Zeng Q, et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006;21:910-20
112. Kugimiya F, Kawaguchi H, Ohba S, et al. GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One 2007;2:e837
113. Kang S, Kumanogoh A. Semaphorins in bone development, homeostasis, and disease. Semin Cell Dev Biol 2013;24:163-71
114. Dacquin R, Domenget C, Kumanogoh A, et al. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS One 2011;6:e26627
115. Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17:1473-80
116. Hayashi M, Nakashima T, Taniguchi M, et al. Osteoprotection by semaphorin 3A. Nature 2012;485:69-74
117. Albers J, Keller J, Baranowsky A, et al. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol 2013;200:537-49
118. Glass DA II, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64
119. Qiang Y-W, Chen Y, Brown N, et al. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol 2010;148:726-38
120. Baron R, Saito H, Gori F. Bone cells crosstalk: noncanonical Roring in the Wnt. Cell Metab 2012;15:415-17
121. Tu X, Joeng KS, Nakayama KI, et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 2007;12:113-27
122. Takada I, Mihara M, Suzawa M, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-[gamma] transactivation. Nat Cell Biol 2007;9:1273-85
123. Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012;18:405-12
124. Cohen-Kfir E, Artsi H, Levin A, et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 2011;152:4514-24
125. Shakibaei M, Shayan P, Busch F, et al. Resveratrol mediated modulation of Sirt- 1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One 2012;7:e35712
126. Pantovic A, Krstic A, Janjetovic K, et al. Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells. Bone 2013;52:524-31
127. Id Boufker H, Lagneaux L, Fayyad-Kazan H, et al. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone 2011;49:1219-31
128. Ignatius A, Schoengraf P, Kreja L, et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1beta. J Cell Biochem 2011;112:2594-605
129. Schoengraf P, Lambris JD, Recknagel S, et al. Does complement play a role in bone development and regeneration? Immunobiology 2013;218:1-9
130. Matsuo K. Eph and ephrin interactions in bone. Adv Exp Med Biol 2010;658:95-103
131. Irie N, Takada Y, Watanabe Y, et al. Bidirectional signaling through ephrinA2- EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 2009;284:14637-44
132. Mundy GR, Yang X. Hedgehog coordination of postnatal osteoclast and osteoblast activities. Dev Cell 2008;14:637-8
133. Mak KK, Bi Y, Wan C, et al. Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Dev Cell 2008;14:674-88
134. Ohba S, Kawaguchi H, Kugimiya F, et al. Patched1 haploinsufficiency increases adult bone mass and modulates Gli3 repressor activity. Dev Cell 2008;14:689-99